Navigation Links
Landmark ONTARGET(TM) Trial Demonstrates Micardis(R) is Equally Effective as Ramipril, with Fewer Discontinuations, in a Broad High-Risk Cardiovascular Population
Date:3/31/2008

The Company's cardiovascular medicine clinical trial program includes ONTARGET, PRoFESS, TRANSCEND and other studies involving more than 75,000 patients in more than 40 countries. These studies were designed to evaluate ways to reduce the risk of damaging events in the heart, brain and other organs due to cardiovascular disease and to uncover new treatment strategies that improve patient outcomes and care.

About Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 137 affiliates in 47 countries and approximately 38,400 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2006, Boehringer Ingelheim posted net sales of US $13.3 billion (10.6 billion euro) while spending approximately one-fifth of net sales in its largest business segment, Prescription Medicines, on research and development.

For more information, please visit http://us.boehringer-ingelheim.com .

About Micardis(R) (telmisartan)

Telmisartan is marketed in the United States by Boehringer Ingelheim as MICARDIS(R) tablets. MICARDIS is indicated for the treatment of hypertension.

USE IN PREGNANCY

When used in pregnancy during the second and third trimesters, drugs that act directly on the renin-angiotensin system can cause injury and even death to the developing fetus. When pregnancy is detected, MICARDIS tablets should be discontinued as soon as possible (see WARNINGS,
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
2. Viatronix V3D-Colon Utilized in Another Landmark Study
3. Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme
4. Hospital Launches Landmark Emergency Medicine Project
5. JACC Identifies DEFER with 5-year Outcomes as Landmark Trial
6. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
7. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
8. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
9. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
10. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 BreedIT Corp (OTC: BRDT), through ... of highly sophisticated agro-breeding solutions for plant breeders and ... Company,s board of directors appointed chemistry and pharmaceutical industry ... member of the board. From 1975 to ...
(Date:1/15/2014)... 2014  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ... System as a non-invasive, wireless continuous glucose monitoring system, ... Chairman and Interim CEO of Echo Therapeutics, will present ... Conference. Mr. Doman will make a ...
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. ... that the applicable waiting period under the Hart-Scott-Rodino Antitrust ... previously announced tender offer by its indirect wholly-owned subsidiary, ... shares of common stock of Solta Medical, Inc. (NASDAQ: ...
Breaking Medicine Technology:BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
(Date:4/23/2014)... about an increase in adolescents, marijuana use following the ... relief. According to a new study at Rhode Island ... states with and without medical marijuana laws, legalizing the ... The study is published online in advance of print ... , "Any time a state considers legalizing medical marijuana, ...
(Date:4/23/2014)... published in the journal Oncotarget , explored ... appearances or their own DNA signatures within the ... to design effective, targeted treatment strategies. , Firstly ... mutation and either the KRAS or BRAF mutation. ... the EGFR gene mutation have that specific mutation ...
(Date:4/23/2014)... of endogenous neural precursor cells cannot alone compensate ... the perspective of neural plasticity, Dr. Yun Xiang ... observed the effects of functional electrical stimulation treatment ... of basic fibroblast growth factor and epidermal growth ... side. The researchers found that functional electrical stimulation ...
(Date:4/22/2014)... sport in the United States with 1 million participants ... Center for Injury Research and Policy at Nationwide Children,s ... occurrence and distribution patterns of basketball-related injuries treated in ... among adolescents and teens. , The study, published online ... data relating to adolescents 13-19 years of age who ...
(Date:4/22/2014)... A recently FDA-approved device has been shown to reduce ... as 50 percent. When coupled with an innovative electrode ... device facilitated the complete elimination of seizures in nearly ... decade-long clinical trials. , That,s good news for a ... U.S. living with epilepsy whose seizures can,t be controlled ...
Breaking Medicine News(10 mins):Health News:RI Hospital physician: Legalizing medical marijuana doesn't increase use among adolescents 2Health News:Non-uniform genetic mutations identified in lung cancers could lead to targeted treatment 2Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 2Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 3Health News:Newly approved brain stimulator offers hope for individuals with uncontrolled epilepsy 2
... ... staggeringly researched book, A Terrible Mistake: The Murder of Frank Olson and the CIA’s Secret ... with LSD and other drugs in a series of biochemical experiments. , ... (Vocus) November 11, 2009 -- Most Americans remember ...
... ... trained to perform the latest minimally invasive single as well as double hip replacement procedures. ... (Vocus) June 29, 2009 ... Center as the 135-year-old downtown hospital,s Medical Director of Joint Replacement and Reconstruction, Dr. ...
... , ... knowledge, relocation management, and design services, Ms. McKenna and the Beyond the Box team can ... “aging in place. , ... November 11, 2009 -- The Washington, DC based relocation and design firm, Beyond the ...
... LONDON, November 11 It,s official, everyone ... from,British Lion Eggs stated that 6 out of 10 women will ... in order to look their very,shimmering best! , ... last pounds, and,still ensure you,re on tip top form. Here,s the ...
... , CHARLOTTE, N.C., Nov. 10 Anthony Asher, MD, ... NC, has co-authored the first evidence-based, multidisciplinary treatment guidelines ... at the Congress of Neurological Surgeons 2009 Annual Meeting ... year by a 20-member panel from various medical specialties. ...
... ... -- "What I,ve Learned About the Throwing Arm in the Last 30 Years" , ... Gulf Breeze, Fla. (Vocus) November 10, ... Institute will hold its inaugural Grand Rounds presentation on November, 19, 2009 at 5:30 ...
Cached Medicine News:Health News:Explosive New Book Exposes the CIA, LSD Experiments and Murder 2Health News:Explosive New Book Exposes the CIA, LSD Experiments and Murder 3Health News:Orthopedic Surgeon Dr. Marc W. Hungerford, a Leading Expert in Field of Avascular Necrosis, Now at Baltimore's Mercy Medical Center 2Health News:Orthopedic Surgeon Dr. Marc W. Hungerford, a Leading Expert in Field of Avascular Necrosis, Now at Baltimore's Mercy Medical Center 3Health News:Relocation Specialists Beyond the Box Team With Nurse to Help Facilitate Senior Moves 2Health News:Relocation Specialists Beyond the Box Team With Nurse to Help Facilitate Senior Moves 3Health News:realbuzz.com Top Tips to Cut the Calories This Christmas Party Season 2Health News:Local Neurosurgeon Co-Authors National Treatment Guidelines for Brain Tumor Patients 2Health News:Orthopaedic Surgeon and AOSSM President Dr. James Andrews to Discuss Injury Prevention 2Health News:Orthopaedic Surgeon and AOSSM President Dr. James Andrews to Discuss Injury Prevention 3
... Easy-On Knee Brace features an adjustable ... 0to 135 in 10 increments. Adjust ... to expose the stop pins and ... thick, self-padded washable fabric with Velcro ...
... BODI™ Dynamic Orthosis is the dynamic ... application over time is proven effective in ... half the time of other therapies. Can ... Orthosis.,Indications: For all joint stiffness and soft ...
... Band uses an aircell to ... tendon helping to relieve symptoms ... tendonitis. Focusing the pressure decreases ... with less constriction of the ...
... Provides shoulder ... range of motion ... rotator cuff tears, ... The shoulder brace ...
Medicine Products: